Camilla Foged

Camilla Foged


Member of:

    Primary fields of research

    Link to press photos of Camilla Foged

    I am leading the research group named Vaccine Design and Delivery at Department of Pharmacy (UCPH). Currently my group comprises 12 internationally recruited researchers and students. My research passion is advanced drug delivery, and we design new vaccine and nucleic acid delivery systems to improve therapy. My group is addressing drug delivery challenges using state of the art technologies, and this has fostered innovative solutions and high-impact publications in drug delivery. My research goal is to improve disease prevention and treatment in the fields of infectious and inflammatory diseases and cancer. We address these aims by imaging-guided design of nanoparticle-based vaccine and nucleic acid formulations through an in-depth and fundamental basic knowledge of how the physicochemical properties of the particles affect their interaction with the environment, i.e. in formulation, in vitro and in vivo. My group is one of the world-leading groups in the area of quality-by-design based engineering of innovative and high-quality nanomedicine formulations. We engage in research projects spanning from early discovery phase projects to first-in-man clinical studies. We address basic scientific questions in the field and are actively engaged in translational research. I am widely recognized nationally and internationally in the field of drug delivery, and I have a well-established and extensive network of collaborators in academia and industry. I have a track record of conducting and leading interdisciplinary research in collaboration with large international consortia. My research has been funded with more than EUR 8 million via prestigious and highly competitive grants from the Danish Research Councils, Universities, private companies, private foundations and EU.

    I am heavily involved in the pre- and post-graduate science-based teaching at the School of Pharmaceutical Sciences. My teaching is in the areas of pharmaceutics, drug formulation and advanced drug delivery. At the BSc programme in Pharmacy, I primarily take part in the teaching in the Bachelor's Project in Pharmacy. I am involved in the teaching at the MSc programmes in Pharmacy, and Pharmaceutical Sciences. This includes the course Advanced Pharmaceutics. I also take part in the teaching at PhD courses offered by the Graduate School of Health and Medical Sciences, UCPH. For a number of years, I have been course leader for the PhD Course Drug Delivery. I am involved in recruitment of high school students via specific lectures for high school classes and supervision of individual high school students (forskerspire). I have supervised more than 200 graduate students, including 74 master students, 109 bachelor students, 13 scholar projects and 21 international students (guest students and ERASMUS students).

    Current research

    See our home page:

    Graduated PhD students

    20: Abhijeet Girish Lokras, Lipid-polymer hybrid nanoparticles as a platform for mRNA vaccines

    19: You Xu, Unravelling the design criteria for targeted nanoparticle-mediated RNA interference therapy for COPD

    18: Reka GeczyChloroform Compatible Polymer Microfluidic Chips for Micro- and Nanoparticle Production

    17: Bruno Borro, Microgels for delivery of antimicrobial peptides 

    16: Donglei Leng, Particle engineering of inhalable dry powder formulations for respiratory combination therapy

    15: Letícia Rodrigues Neibecker, Development of Novel Vaccine Carriers: Physicochemical and Biological Characterization of Hexosomes

    14: Birte Martin-Bertelsen, Structural Characterization of Lipid-based Adjuvants for Subunit Vaccines: Structure Activity Relationship for Analogues of the Mycobacterial Cell-Wall Lipid Monomycoloyl Glycerol

    13: Signe Tandrup Schmidt, Targeted delivery of cytotoxic T-lymphocyte-inducing vaccines to cross-presenting dendritic cells. Design and characterization of lipid-based adjuvants

    12: Gry Persson, Outer membrane vesicles and their potential as vaccine against Gallibacterium anatis

    11: Rie Selchau KallerupStructure Activity Relationship (SAR) of Immunostimulating Compounds: Analogues of the Synthetic Immunostimulator Trehalose 6,6'-dibehenate (TDB)

    10: Jorrit Jeroen Water, Nanoparticle-based approaches for delivery of antimicrobial peptides

    9: Feng Wan, Design of Injectable PLGA Microparticles by the Spray Drying Process. Role of solvent properties and nozzle design

    8: Stefano Colombo, Investigations of Nanocarrier-Mediated Cellular siRNA Delivery Processes Using Advanced Analytical Approaches

    7: Pall Thor Ingvarsson, Formulating the DDA/TDB Liposomal Adjuvant into Nanocomposite Solid Microparticles for Pulmonary Vaccination: Dry Powder Stabilization and in vitro Interactions with Pulmonary Epithelial Cells

    6: Mette Hamborg, Physical Stability of Subunit Vaccines:Interactions between Liposomal Adjuvants and Protein Antigens

    5: Xiaona Jing, Peptide-assisted (Particulate) Drug Delivery Systems for Delivery of Biomacromolecules

    4: Nina Østergaard Knudsen, Advanced targeting of liposomes to the skin

    3: Linda Boye Jensen, Design and investigation of nanoparticles for targeted delivery of small interfering RNA (siRNA)

    2: Pernille Nordly, Modulation of the adjuvant activity of DDA/TDB liposomes with immunostimulating ligands targeting dendritic cell receptors

    1: Dennis Christensen, Optimization and characterization of adjuvant formulations based on cationic liposomes and immunomodulating compounds

    Master Students

    84: Elena Grobecker, 2024, Ongoing

    83: Houjia Hu, 2024, Ongoing

    82: Katrine Melgaard, 2024, Ongoing

    81: Anja Gjøl, 2024, Investigation of the effect of antibiotic combinations and concentrations used in CEF cell-based manufacturing processes

    80: Frida Helene Bogen Harberg, 2024, Thiol-ene microfluidic chips for manufacturing of lipid nanoparticles loaded with siRNA and mRNA

    79: Þórdís Danielsdóttir van der Lint, 2023, Design of mRNA-loaded nanoparticle delivery systems for breast cancer vaccination: In vitro comparison of transfection efficiency, cytotoxicity and immune activation

    78: Beatriz Alves Dias, 2023, A quality-by-design approach towards the optimization of lipid polymer hybrid nanoparticles for mRNA delivery

    77: Ervin Paknejadi, 2023, Biodistribution studies of mRNA vaccine candidates

    76: Jiaqi Hong, 2022, A Lymph Node Targeted DNA Nanoflower Vaccine for Cancer Immunotherapy

    75: Thomas Rønnemos Bobak, 2022, Microfluidic production and in vivo imaging of lipidoid-polymer hybrid nanoparticles

    74: Siqi Feng, 2022, Improving the aerosol performance of dry powder inhaler formulations of the cationic liposomal adjuvant CAF®01 using leucine as shell-forming excipient

    73: Saahil Sandeep Baghel, 2022, Development and optimization of messenger RNA-loaded lipidoid-polymer hybrid nanoparticles

    72: Astrid Walter Christiansen, 2022, Formulation and Characterization of Lipid Nanoparticles for Pulmonary Delivery of Messenger RNA

    71: Zhenning Shi, 2022Investigation of the Biophysical Interaction between Nanoparticles and Mucus and Pulmonary Surfactant Layers

    70: Marlene Pettha Thanthrige, 2021, Investigating the effect of incorporation of an immunopotentiator in mRNA-loaded C12-200-based lipid nanoparticles

    69: Thomas Lindebo Holm, 2021, T cell directed therapies in inflammatory skin diseases

    68: Olivia Amanda Oest Müllertz, 2021, Elucidating the influence of surface charge of liposome-based adjuvants on mucosal and systemic immune responses following intrapulmonary immunization

    67: Enise Tugba Turan, 2021, Investigation of the Effect of L-Leucine on The Physicochemical Properties of Spray- Dried siRNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles

    66: Akash Chakravarty, 2021, Development of analytical methods for simultaneous quantification of single- and double-stranded RNA loaded in nanoparticles and internalized in cells

    65: Mevla Sadik Øzer, 2021, Advanced physicochemical characterization of lipidoid-polymer hybrid nanoparticles for intracellular delivery of mRNA: A study of monolayers at the interface

    64: Caroline Matilde R Lundegaard, 2021, Formulation of CAF adjuvants with the STING agonist c-di-GMP and its efficacy as pan-viral prophylaxis

    63: Abishek Wadhwa, 2021, Microfluidic-based formulation design and manufacturing of an immunopotentiating mRNA vaccine

    62: Dennis Sulbæk, 2020, Evaluation of the effect of modification of antigen charge on adsorption  to CAF01 liposomes

    61: Anas Samir Mohammad Aljabbari, 2020, Structural characterization of lipidoid-polymer hybrid nanoparticles for intracellular delivery of siRNA

    60: Susanne Pihl, 2020, Evaluation of anti-PEG antibody responses in the non-clinical and clinical development of PEGylated therapeutics - Impact of pre-existing and treatment-emerging anti-PEG antibodies and their impact on pharmacokinetics and efficacy

    59: Guillermo Cano, 2019, Identification of factors of importance for the design and dosing of an inhalable solid dosage for of the tuberculosis subunit vaccine candidate H56/CAF01

    58: Marthe Simonsen, 2019, Design of novel siRNA delivery systems based on lipid-polymer hybrid nanoparticles for RNAi therapy of chronic obstructive pulmonary disease

    57: Pauliina Ranne, 2019, Comparison of Lipid-Polymer Hybrid Nanoparticles Formulated by Single and Double Emulsion Solvent Evaporation Method 

    56: Abhijeet Lokras, 2019, A quality-by-design approach for loading an anti-inflammatory siRNA in lipidoid-polymer hybrid nanoparticles 

    55: Katharina Wørzner, 2019, Determining the effect of attractive electrostatic interactions between lysozyme and liposomal adjuvants on the immune response in vivo

    54: Caroline Plesner Jacobsen, 2019, The Chain Length of Novel Lipidoids, Intended for Efficient and Safe Intracellular Delivery of siRNA, is Decisive for in vitro Transfection Potential and Immunogenicity

    53: Johanna Hvannastein, 2018, Modification of Antigen Isoelectric Point: Influence on Antibody and T Cell Responses Induced by Cationic Liposomes

    51-52: Diana C. Ljungkvist and Catharina Razer, 2018,Pharmacodynamics and Pharmacokinetics in Galleria mellonella Larvae: Evaluation of Liquid Chromatography – Mass Spectrometry for Quantification of Meropenem in Larval Hemolymph and Tissue-Lysed Samples

    50: Sarah Larsen, 2018, The Role of Sestrin1 and Sestrin2 in Cell Death Mediated by Cisplatin, a Flow Cytometric Study

    49: Henrik Vester, 2018, Development of hydrogel formulations for drug delivery using biorthogonal click chemistry

    48: Ann-Kathrin Stein, 2018, A novel hapten as a vaccine against methamphetamine use disorder - An in vivo behaviourak study and synthesis and design optimisation

    47: Simon Papai, 2018, Lipid–polymer hybrid nanoparticles (LPNs) for efficient intracellular delivery of antisense oligonucleotides

    46: Agnieszka Samsel, 2018, Optimization of TNF-α siRNA-loaded lipidoid-PLGA hybrid nanoparticles: A novel technique for quantification of siRNA encapsulation efficiency

    45: Shaquib Rahman Ansari, 2018, Design and Optimization of Gadoteridol-Loaded DDA/TDB Liposomes: A Quality-by-Design Approach

    44: Karolina Sanicka, 2018, Identification of factors of importance for the design of an inhalable solid dosage form of the tuberculosis subunit vaccines H56/CAF04 and H56/CAF09

    43: Cypriane Dormenval, 2018, Identification of factors of importances for the design of an inhalable solid dosage form of small interfering RNA-loaded lipidoid-poly(DL-lactic-co.glycolic acid) hybrid nanoparticles

    42: Malene Aaby Neustrup, 2017, Formulation and Characterisation of Nanoemulsion-Based Adjuvants Mediating Vaccine-Induced CD8+ T-Cell Responses

    41: Sabrine Fuglsbjerg Ramdal Lægteskov, 2017, Delivery of a combination of siRNA and peptide for the treatment of rheumatoid arrhritis - Formulaion optimization 

    40: Sarah Tejlmann, 2016, Formulation and characterization of stabilized nucleic acid lipid particles for delivery of siRNA: Comparison with lipoplexes and lipid-polymer hybrid nanoparticles

    39: Pernille Rønde Jensen, 2016, Degradation profiles of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein-based Antigen CTH522: Comparison of three GMP-produced batches

    38: Camilla Line Olsen, 2016, Formulation, Charaterization and In Vivo Test of CAF Adjuvants             

    37: Michaela Czort, 2016, Solid Lipid Particles for Oral Delivery of Vaccines. Particle preparation, characterization and quantification and protein characterization

    36: Elisabeth Bergholt, 2016, CL-HA hydrogels incorporated with PLGA nanoparticles for controlled release in the treatment of rheumatoid arthritis

    35: Carla Roches, 2014, Biophysical characterization of liposomal adjuvants based on dimethyldioctadecylammonium (DDA) bromide and monomycoloyl glycerol (MMG): Differential scanning calorimetry (DCS), small angle X-ray scattering (SAXS) and cryo transmission electron microscopy (cryo-TEM) studies.

    34: Jia Shi, 2014, Effect of the trehalose-6, 6’dibehenate (TDB) analogue modification on the physicochemical properties of a cationic adjuvant system

    33: Przemyslaw Jedrzej Irlik, 2013, Mucosal vaccination: Interactions between mucosal epithelium and mucosal vaccines. Mechanistic studies

    32: Camilla Hasling Frandsen, 2013, Vancomycin-Loaded Multi-and Unilamellar Cationic Liposomes: Treatment of Staphylococcus Aureus

    31: Kasper Karlsen, 2013, Identification and characterization of novel cationic adjuvant formulations: Toll-like receptor ligands incorporated into liposomes for use against intracellular infections

    30: Elizaveta Kamynina, 2013, Oromucosal drug delivery using liposomes for alleviation of xerostomia

    28-29: Angelos Moschidis and Xing Hanyue, 2013, Methotrexate-loaded deformable liposomes for dermal delivery

    27: Cecilie Maria Madsen, 2012, The effect of the acyl chain length of trehalose-6,6’-dibehenate on the physicochemical and immunopotentiating properties of DDA/TDX liposomes

    26: Katrine Vidensen Bjørklund, 2012, Interactions between liposomal adjuvants and protein antigens: Effect of liposome surface charge, protein physicochemical properties and heating

    25: Signe Tandrup Schmidt, 2012, Formulation of CAF09 to enhance the CD8+ T-cell response after subcutaneous immunization

    24: Helene Brøndum Pedersen, 2012, Liposome-based cationic adjuvants: Interactions with antigens. The effect of charge

    23: Mona Mekki, 2012, siRNA delivery by non-viral carriers

    22: Matias Rosenkvist, 2011, Spray Dried Powders for Pulmonary Delivery: A Comparative Study of Methods for Particle Size

    21: Mehtap Tellioglu, 2011, Encapsulation of Ovalbumin into DDA/TDB Liposomes Prepared by the Double Emulsion Solvent Evaporation Method. Characterization of Interactions at the Interface

    20: Ida Svahn Rasmussen, 2011, Effect of liposomal charge on mucosal vaccine delivery: An in vitro study

    19: Cathrine Roer, 2010, Controlled Surface Modifications of PLGA Nanoparticles Using Cell Penetrating Peptides for Efficient Delivery of siRNA

    18: Veronika Gadzhyeva, 2010, Karakterisering af PAMAM-siRNA komplekser af generationer G1, G4 og G7 ved forskellige molære ratioer

    16-17: Tanja Pedersen & Rukiye Karaman, 2010, Karakterisering af DDA/TDB liposomer ved inkorporering af forskellige størrelser polynukleotider

    14-15: Stine Rønholt & Ragnhild Djønne Salte, 2009, Skin penetration of PEGylated liposomes

    12-13: Esra Alici Pedersen & Tayba Sajid Khilji, 2009, Characterization of incorporation of monomycolylglycerol in dimethyldioctadecylammoniumbromide liposomes

    11: Anders Simonsen, 2009, Interaction between novel cell-penetrating peptides and anionic liposomes: Thermodynamic and structural assessment

    10: Rasmus Bjerregaard-Andersen, 2009, Interaction of a new class of cell-penetrating peptides (CPP) with model lipid membranes

    9: Ditte Marie Krogh Jensen, 2008, Spray-drying Preparation of Microparticles Containing siRNA-loaded PLGA Nanoparticles

    8: Andreas Tue Ingemann Jensen, 2008, Neutral Conventional and Stealth Liposomes for i.v. Administration of siRNA

    7: Ali Rehman, 2007, Spray drying of chitosan/siRNA nanoparticles with mannitol

    6: Sibel Tokmak, 2007, HL10 Liposomes as Drug Delivery System for siRNA-Chol

    5: Henriette Baun Madsen, 2006, Preparation and Characterization of the PROVAXTM adjuvant

    4: Elisabeth Giger, 2006, Long-circulating liposomes for secretory phospholipase A2 triggered release of siRNA in inflamed tissue – in vitro studies of TNF-α silencing in the murine macrophage cell culture J774A.1

    3: Peter Merrild, 2004, Interaction between antimicrobial peptides and biological membranes

    2: Bettina Bruun, 2001, Polymeric delivery of camptothecin analogs and rabbit carboxylesterase

    1: Jeannet Kall, 2001, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of polyamine analogs

    ERASMUS Students

    24: Elena Lopez, 2023, Ongoing

    23: Lauran Merchiers, 2023, Adjuvant-modified lipid nanoparticles for mRNA delivery – Optimization using a quality by design approach

    22: Louise Despiegelaere, 2022, Design of novel siRNA delivery systems based on lipid-polymer hybrid nanoparticles for RNAi therapy of chronic obstructive pulmonary disease

    21: Ivo Tielbeek, 2022, Replacing conventional helper lipids in mRNA-loaded lipid nanoparticles to improve intracellular delivery and in vivo transfection efficiency

    20: Sandra López Cerdá, 2021, Development of messenger RNA-loaded lipidoid-polymer hybrid nanoparticles

    19: Laure Harinck, 2020, Optimization of a powder-based solid dosage form of TNF-a siRNA-loaded lipidoid-polymer hybrid nanoparticles designed for pulmonary delivery

    18: Elisa De Meester, 2019, PLGA Nanoparticles as Delivery System for Antimicrobial Peptides

    17: Jenny Lai, 2018, Nanoparticle-Mediated Co-Delivery of Small Interfering RNA and Heat Shock Protein 70-Peptide B29 for the Treatment of Rheumatoid Arthritis

    16: Delphine Van Eetvelde, 2018, In vitro release assesment of siRNA from lipid-polymer hybrid nanoparticles

    15: Elisabeth Bombarda, 2017, Design of a thermostable TB vaccine for pulmonary delivery: Comparison between the biophysical stability of fusion protein antigen H56 and OVA model antigen

    14: Hannelore Van Eygen, 2017, Investigations into the in vitro release kinetics of siRNA from Lipid–polymer hybrid nanoparticles (LPNs)

    13: Francesca Gavins, 2017, Design of a mucosal adjuvant based on glycol chitosan-coated lipid-polymer hybrid nanoparticles for vaccination against chlamydia

    12: Emma Putteman, 2016, Assesment of stability and release kinetics of siRNA loaded into lipid-polymer hydrid nanoparticles

    11: Danielle Dennehy, 2015, PLGA nanoparticles for siRNA delivery in vitro

    10: Elize Van Driessche, 2015, Preparation and optimization of lipid-PLGA nanoparticles for siRNA delivery

    9: Monica Agnoletti, 2015, Design of siRNA-loaded dendriplexes in microparticles prepared by microfluidics and spray drying

    8: Tamanna Lashkari, 2014, Dry powder stabilization of freeze-dried CAF01 liposomes by trehalose and/or inulin

    7: Silke Roovers, 2014, Biophysical characterization and understanding of the aggregation mechanism of model antigen ovalbumin and vaccine candidate NN-GBS

    6: Olivier de Troyer, 2013, Biophysical characterization of the mycobacterial cell wall lipid monomycoloyl glycerol

    5: Erik Oude Blenke, 2012, Cell Penetrating Peptidomimetic-Functionalized Lipid Systems for siRNA Delivery

    4: Michelle Viaene, 2012, Effect of liposomal charge on pulmonary vaccine delivery

    3: Ivo Verlinden, 2011, Formulation and in vivo effectiveness of the CAF05 adjuvant in a ferret influenza challenge model

    2: Joscha Griger, 2009, Toxicogenomic effects of polymeric siRNA delivery in vitro

    1: Hayley Rose March, 2007, Assessment of the Structure of the M. Tuberculosis antigen Ag85b-ESAT-6 and the changes in secondary structure on interaction with DDA/TDB Liposomes 

    Scholar students

    13. Abishek Wadhwa, 2020-2021

    12. Veronica Martini, 2016-2017

    11. Emily Falkenberg, 2016-2017

    10: Sofie Lillelund Ovesen, 2016-2017

    9: Sarah Justesen, 2013-2014

    8: Mikkel Lohmann Schiøth, 2012

    7: Lasse Bengtson, 2010-2011

    6: Anders Riber Bojsen, 2009-2010

    5: Signe Tandrup Schmidt, 2009-2010

    4: Maja Hauge Nielsen, 2008-2009

    3: Martin Blaedel, 2007

    2: Tejs Pedersen, 2007

    1: Rie Selchau Kallerup, 2004-2005


    Possible conflicts of interest

    Member of the mRNAVAC Working Party, Council of Europe, EDQM, European Pharmacopoeia Department, Strasbourg, France

    2 Dec 2022 → …

    Member of the committee for vaccination, The Danish Health Authority, Copenhagen, Denmark

    Nov 2021 → …

    Member of expert group for COVID-19 vaccination of children 5-11 years old, The Danish Health Authority, Copenhagen, Denmark

    23 Nov 2021 → Jan 2022

    COVID-19: Member of expert group for revaccination, The Danish Health Authority, Copenhagen, Denmark

    27 Aug 2021 → Jan 2022

    Member of expert group for COVID-19 vaccination of children 12-15 years old, The Danish Health Authority, Copenhagen, Denmark

    9 Jun 2021 → 20 Aug 2021

    Consultant, Camilla Foged Consulting, Denmark

    26 Jul 2020 → …

    Member of the American Association of Pharmaceutical Scientists (AAPS)

    Member of the Controlled Release Society (CRS)

    ID: 1299454